Arthneeti

Par Drugs & Chemicals Q2 FY27 Share Price & Earnings Call Analysis

₹113.20+3.91% today
Market cap
₹139 Cr
P/E
10.72
ROE
9.95%
PEG
-4.89
Price to sales
1.29
Debt to equity
0.00
52W high / low
₹168 / ₹78.6
Sales growth (5Y)
11.28%
EBITDA margin
17.06%
Net profit margin
10.13%
Promoter holding
73.41%
Sales (last year)
₹108 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Par Drugs & Chemicals rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Par Drugs & Chemicals.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Par Drugs & Chemicals

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Par Drugs & Chemicals

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +74.21%74.21%74.21%73.37%73.37%73.37%73.37%73.37%73.41%73.41%73.41%73.41%
FIIs +0.07%0.07%0.32%0.09%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
DIIs +0.00%0.05%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.09%0.09%
Public +25.73%25.68%25.47%26.54%26.63%26.63%26.63%26.63%26.59%26.59%26.51%26.51%
No. of Shareholders7,0207,4038,0228,75717,18915,47214,88714,28013,76113,22212,78212,672

Financials of Par Drugs & Chemicals

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +25.8924.0022.8222.6134.6621.3822.3326.0528.6629.3419.6131.2827.43
Expenses +18.5318.7716.7218.3723.2519.9519.9022.4922.6023.2918.1724.9122.92
Operating Profit7.365.236.104.2411.411.432.433.566.066.051.446.374.51
OPM %28.43%21.79%26.73%18.75%32.92%6.69%10.88%13.67%21.14%20.62%7.34%20.36%16.44%
Other Income +0.050.23-0.050.071.020.270.791.840.481.330.360.940.00
Interest0.030.020.050.020.030.010.020.020.050.010.040.020.02
Depreciation0.850.870.890.900.910.910.920.900.940.930.930.960.94
Profit before tax6.534.575.113.3911.490.782.284.485.556.440.836.333.55
Tax %25.27%25.16%27.20%25.07%25.15%24.36%27.63%25.67%25.59%25.47%-3.61%25.59%25.92%
Net Profit +4.893.423.722.538.600.581.653.334.134.800.854.712.63
EPS in Rs3.972.783.022.066.990.471.342.713.363.900.693.832.14

Financials of Par Drugs & Chemicals

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +33334942465661759696101104108
Expenses +26264034384645597873818789
Operating Profit77888916161823201718
OPM %22%22%17%19%18%17%26%22%19%24%19%17%17%
Other Income +0000002000243
Interest4422211000000
Depreciation2333333333444
Profit before tax11333615131520181717
Tax %27%58%42%42%24%21%21%27%25%26%26%24%
Net Profit +1022351291114131313
EPS in Rs1.650.783.432.782.793.879.447.499.2111.7810.8610.6510.56
Dividend Payout %0%0%0%0%0%32%0%0%0%0%0%0%

Financials of Par Drugs & Chemicals

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital3333466121212121212
Reserves99111225344648597387100107
Borrowings +383631291268000000
Other Liabilities +9101210111316191816201719
Total Liabilities595856545160767989102119129139
Fixed Assets +45434239363430343841393636
CWIP0000015000010
Investments0000000000252735
Other Assets +13151415152542445060556568
Total Assets595856545160767989102119129139

Financials of Par Drugs & Chemicals

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +97942812813201616
Cash from Investing Activity +-0-0-2-1-0-10-3-7-6-25-2
Cash from Financing Activity +-9-5-8-4-212-100000
Net Cash Flow-11-10-0714-5614-914
Free Cash Flow9674261246141514
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit127%91%116%59%34%90%98%66%97%108%106%125%

Financials of Par Drugs & Chemicals

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days838161756781759065526042
Inventory Days11115869838145506049455845
Days Payable1841831351079496112135735810469
Cash Conversion Cycle1057-5515530131440401519
Working Capital Days6166-46-261339246150403931
ROCE %10%9%12%11%12%16%25%22%23%25%18%15%

Continue your research

What Par Drugs & Chemicals's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals